Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

• ClinicalTrials.gov Identifier: NCT02037529
• Recruitment Status: Suspended
• First Posted: January 16, 2014
• Last Update Posted: May 26, 2022
• Sponsor: Academic and Community Cancer Research United
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Academic and Community Cancer Research United

Study Description

Brief Summary:

This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Condition or disease	Intervention/treatment	Phase
Breast Adenocarcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7	Drug: Eribulin Mesylate; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment	Phase 3

Detailed Description:

PRIMARY OBJECTIVES:

I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witheribulin mesylate (eribulin) and standard weekly paclitaxel at 12 weeks.

II. To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).

SECONDARY OBJECTIVES:

I. To compare overall survival, progression free survival (PFS), objective response rate (ORR), duration of response (DOR), and time to treatment failure (TTF) in patients receiving eribulin versus standard weekly paclitaxel.

II. To compare the 12 month rate of disease progression in patients receiving eribulin versus standard weekly paclitaxel.

III. To evaluate the clinical value and feasibility of collecting patient-reported symptom toxicity information via the Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

IV. To further validate the PRO-CTCAE sensory neuropathy items. V. To compare patient reported neurotoxicity between arms using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) instrument.

VI. To assess the toxicities in patients receiving eribulin versus standard weekly paclitaxel.

CORRELATIVE OBJECTIVES:

I. To compare new metastasis free survival in patients receiving eribulin versus standard weekly paclitaxel.

II. To explore the relationship between common single nucleotide polymorphisms in FGD4, FZD3, and VAC14 as predictors of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).

III. To evaluate circulating nucleosomes and the apoptosis associated M30 neo-epitope as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.

VI. To evaluate tubulin isotype expression, mutations, and signaling pathway modifications in tumor tissue as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
• Actual Study Start Date: January 17, 2014
• Actual Primary Completion Date: June 22, 2020
• Estimated Study Completion Date: September 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A (eribulin mesylate); Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.	Drug: Eribulin Mesylate; Given IV; Other Names: B1939 Mesylate; E7389; ER-086526; Halaven; Halichondrin B Analog; Other: Laboratory Biomarker Analysis; Correlative studies; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment
Experimental: Arm B (paclitaxel); Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Other: Laboratory Biomarker Analysis; Correlative studies; Drug: Paclitaxel; Given IV; Other Names: Anzatax; Asotax; Bristaxol; Praxel; Taxol; Taxol Konzentrat; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment

Outcome Measures

Primary Outcome Measures :

1. Patient-reported maximum score [ Time Frame: Up to 12 weeks after treatment initiation ]
   The patient-reported maximum score (post baseline) across Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) items for each patient will be computed over the first 12 weeks and compared between arms using a two-sample independent samples t-test.
2. Validation of germline EPHA5 polymorphism (rs7349683) [ Time Frame: Up to 5 years ]
   The Cox score test will be used to test the association between the cumulative dose level triggering toxicity and the genotype. The goal is to validate the EPHA5 rs7349683 single neucleotide polymorphism (SNP).

Secondary Outcome Measures :

1. Overall survival (OS) [ Time Frame: From randomization to death due to any cause, assessed up to 5 years ]
   The primary analysis will use the stratified log-rank tests, as described for overall survival. As a secondary analysis we will use a multivariable Cox proportional hazard model to estimate adjusted hazard ratios for eribulin mesylate over standard weekly paclitaxel, study stratification factors, and covariates for known prognostic factors, including disease free interval and visceral versus non-visceral metastases. Survival functions will be summarized using the Kaplan-Meier method according to treatment group.
2. Objective tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: Up to 5 years ]
   The primary analysis will use the Cochran-Mantel-Haenszel chi-squared test with study stratification factors. Secondary analyses will use logistic regression to test differences in proportions while controlling for the covariates. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
3. Duration of response [ Time Frame: Up to 5 years ]
   Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
4. Time to treatment failure [ Time Frame: Up to ]
   Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
5. Incidence of treatment related adverse events [ Time Frame: Up to 30 days after last dose assessed by CTCAE version 4.0 ]
   The primary analysis will use the Cochran-Mantel-Haenszel chi-squared test with study stratification factors. Secondary analyses will use logistic regression to test differences in proportions while controlling for the covariates. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
6. Time to new metastasis [ Time Frame: Up to 5 years ]
   Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
7. Progression free survival assessed by RECIST 1.1 criteria [ Time Frame: From randomization to progression or death due to any cause, whichever occurs first, assessed up to 5 years ]
   Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
8. Patient reported neurotoxicity [ Time Frame: Up to 24 weeks ]
   Additional analyses will include the previously described analysis conducted over the first 24 weeks; a comparison of the incidence of patient-reported maximum score >= 3 between arms through 12 and 24 weeks using chi-squared testing for each item; and a comparison of the time to patient-reported score >= 3 between arms using Kaplan-Meier and log-rank analyses. Further, these three endpoints will be compared between patient- and clinician-report overall and within arms using appropriate paired analyses.
9. Validation of PRO-CTCAE sensory neuropathy item [ Time Frame: At baseline, 12 and 24 weeks ]
   The PRO-CTCAE sensory neuropathy items will be further validated by computing Pearson correlations between each item and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20 )sensory scale score at baseline, 12 and 24 weeks.

Other Outcome Measures:

1. New metastasis free survival [ Time Frame: Up to 5 years ]
   Will be summarized using the Kaplan-Meier method according to treatment group.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Informed consent document signed and dated by patient
• Histologic confirmation of invasive adenocarcinoma originating in the breast
• Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapy
• Clinical or radiographic evidence of disease progression
• Documentation of HER2 negative breast cancer at the time of protocol registration; (Note: HER2 negativity is defined as 0 or 1+ by immunohistochemistry OR nonamplified or equivocal by fluorescence in situ hybridization [FISH]; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
• Known hormone receptor status at the time of protocol registration; (Note: estrogen receptor [ER] and/or progesterone receptor [PgR] status are considered positive with a cut-off of >= 1% invasive tumor cells; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
• Patients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, targeted therapy, or biologic therapy to grade =< 1, including peripheral neuropathy, with the exception of alopecia (any grade permissible)

• No more than one prior chemotherapy regimen for advanced or metastatic breast cancer is allowed; prior chemotherapy for metastatic disease must have been completed >= 14 days prior to randomization

  • Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered as a preplanned treatment, given concomitantly, sequentially or both, is considered one regimen
  • Planned neoadjuvant chemotherapy and postoperative adjuvant chemotherapy is considered one regimen
  • If the dosing of one or more of the chemotherapy components of a regimen must be reduced for toxicity, the modified version of the original regimen is not considered a new regimen
  • If one or more of the chemotherapy components of a regimen must be omitted for toxicity, the modified version of the original regimen is not considered a new regimen
  • If one of the chemotherapy components of a regimen must be replaced with another similar drug of the same therapeutic class, the modified version of the original regimen is not considered a new regimen; however, if a new component, dissimilar to any of the original components, is added to the regimen, the modified version is considered a new regimen
  • If chemotherapy is interrupted for surgery or radiotherapy and then continues with an unchanged schedule and components, treatment is considered as one regimen despite the interruption

• Prior treatment may include a taxane as per the following criteria:

  • Prior taxane (including paclitaxel) in the adjuvant or neoadjuvant setting is allowed, provided that the interval between the completion of (neo)adjuvant therapy and disease recurrence is > 12 months
  • Prior taxane in the metastatic setting is allowed, provided that the agent administered in the metastatic setting was not standard paclitaxel
• Any number of prior endocrine therapies is allowed and must be discontinued prior to randomization
• Any number of biologic therapies (e.g., bevacizumab) or immunotherapies is allowed in the absence of co-administered chemotherapy and must have been completed >= 28 days prior to randomization
• Prior treatment with an investigational agent is allowed but must have been completed >= 28 days prior to randomization with resolution of all treatment-related toxicities to grade =< 1.
• Minor surgical procedures must be completed >= 7 days prior to randomization with documentation of adequate recovery from associated complications to grade =< 1; these include (but are not limited to) laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, endoscopic ultrasonography, skin biopsy, percutaneous needle biopsy, and routine dental procedures; as a precautionary measure, it is recommended, but not strictly required, that placement of a central venous access device, thoracentesis, or paracentesis be done 7 days before the initiation of protocol directed chemotherapy with documentation of adequate recovery from associated complications to grade =< 1
• Major surgical procedures and open biopsies must be completed >= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =< 1
• Prior radiotherapy must be completed >= 14 days prior to randomization with documentation of adequate recovery from associated toxicities to grade =< 1
• Treatment with bisphosphonates or denosumab is allowed and recommended per the standard of care
• Therapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparin
• Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as >= 1.0 cm by computed tomography (CT) scan or >= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be >= 1.5 cm in the short axis when assessed by CT scans with slice thickness =< 0.5 cm
• Non-measurable lesions include the following: small lesions (longest diameter < 1.0 cm for all lesions other than pathologic lymph nodes, which are >= 1.0 cm and < 1.5 cm in the short axis), bone metastases, pleural effusions, pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, lymphangitis pulmonis, lymphangitis cutis, and abdominal masses not followed by CT or magnetic resonance imaging (MRI)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Life expectancy of > 12 weeks
• Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =< 28 days of study registration
• Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =< 28 days of study registration
• Obtained =< 7 days prior to registration: Absolute neutrophil count >= 1500/uL
• Obtained =< 7 days prior to registration: Platelet count >= 100,000/uL
• Obtained =< 7 days prior to registration: Hemoglobin >= 9 g/dL
• Obtained =< 7 days prior to registration: Total bilirubin =< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert?s syndrome
• Obtained =< 7 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferases [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN except in the case of liver metastases, where =< 5 x ULN is allowed
• Obtained =< 7 days prior to registration: Creatinine =< 2.0 mg/dL or creatinine clearance > 50 mL/min
• Obtained =< 7 days prior to registration: Corrected QT (QTc) interval =< 500 msec on the baseline electrocardiogram

• Negative pregnancy test done =< 72 hours prior to registration for women of childbearing potential only; Note: all female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation >= 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy)

  • Female subjects of child-bearing potential must agree to use highly effective contraception during the study treatment and for 3 months after the final dose of study treatment; female subjects exempt from this requirement are subjects who practice total abstinence; if currently abstinent, the subject must agree to use a double barrier method of contraception (i.e., condom and occlusive cap [diaphragm or cervical/vault caps]) with spermicide or until they are established on highly effective contraception for at least one menstrual cycle if they become sexually active during the study treatment and for 3 months after the final dose of study treatment

  • Highly effective contraception includes:

    • Placement of intrauterine device or system
    • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide
    • Vasectomized partner with confirmed azoospermia
  • Male subjects and their female partner who are of child-bearing potential (as defined above), and are not practicing total abstinence, must agree to use highly effective contraception during study treatment and for 3 months after the final dose of study treatment; if currently abstinent, the subject must agree to use a double barrier method of contraception if they become sexually active, or until they are established on highly effective contraception as described above
• Ability to complete questionnaire(s) independently or with assistance
• Willingness to provide blood and tissue samples for correlative research purposes; (Note: these tissue samples are from archived tissue, if available; new biopsies are not required)
• Ability to comprehend and respond to questions using a telephone keypad

Exclusion Criteria:

• Prior malignancy, other than carcinoma in situ of the cervix and non-melanoma skin cancers, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously, there is no subsequent evidence of recurrence, and the patient is considered by a physician to be at < 30% risk of relapse

• Any of the following:

  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
• Presence of a serious nonhealing wound, ulcer, or bone fracture
• History of Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 hypersensitivity to paclitaxel or Cremophor EL
• Pre-existing peripheral neuropathy grade ?= 2 at registration
• Significant cardiovascular impairment (e.g., New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia)
• Subjects with known positive human immunodeficiency virus (HIV) status
• History of stroke or transient ischemic attack =< 6 months prior to registration
• History of uncontrolled seizures; (Note: patients are eligible for the study if the seizures are well controlled with standard medications)
• Severe or uncontrolled intercurrent illness/infection
• Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer
• Prior exposure to eribulin mesylate

Contacts and Locations

Locations

United States, Arizona

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

United States, Delaware

Christiana Care Health System-Christiana Hospital

Newark, Delaware, United States, 19718

United States, District of Columbia

MedStar Georgetown University Hospital

Washington, District of Columbia, United States, 20007

United States, Florida

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

United States, Illinois

University of Illinois

Chicago, Illinois, United States, 60612

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States, 60637

Illinois CancerCare-Peoria

Peoria, Illinois, United States, 61615

Carle Cancer Center NCI Community Oncology Research Program

Urbana, Illinois, United States, 61801

United States, Iowa

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, United States, 52403

Iowa-Wide Oncology Research Coalition NCORP

Des Moines, Iowa, United States, 50309

Siouxland Regional Cancer Center

Sioux City, Iowa, United States, 51101

United States, Kansas

Cancer Center of Kansas - Wichita

Wichita, Kansas, United States, 67214

United States, Louisiana

Ochsner NCI Community Oncology Research Program

New Orleans, Louisiana, United States, 70121

United States, Maine

Lafayette Family Cancer Center-EMMC

Brewer, Maine, United States, 04412

United States, Michigan

Cancer Research Consortium of West Michigan NCORP

Grand Rapids, Michigan, United States, 49503

United States, Minnesota

Essentia Health NCI Community Oncology Research Program

Duluth, Minnesota, United States, 55805

Mayo Clinic

Rochester, Minnesota, United States, 55905

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, United States, 56303

United States, Missouri

University of Missouri - Ellis Fischel

Columbia, Missouri, United States, 65212

Heartland Regional Medical Center

Saint Joseph, Missouri, United States, 64507

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

Heartland Cancer Research CCOP

Saint Louis, Missouri, United States, 63131

United States, Nebraska

Cancer Alliance of Nebraska

Omaha, Nebraska, United States, 68106

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198

United States, New Hampshire

New Hampshire Oncology Hematology PA-Hooksett

Hooksett, New Hampshire, United States, 03106

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States, 03756

United States, New York

Hematology Oncology Associates of Central New York-East Syracuse

East Syracuse, New York, United States, 13057

United States, North Carolina

Mission Hospital-Saint Joseph Campus

Asheville, North Carolina, United States, 28801

Cone Health Cancer Center at Alamance Regional

Burlington, North Carolina, United States, 27215

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States, 27599

Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, United States, 27534

FirstHealth of the Carolinas-Moore Regional Hospital

Pinehurst, North Carolina, United States, 28374

Novant Health Forsyth Medical Center

Winston-Salem, North Carolina, United States, 27103

United States, Oklahoma

Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, United States, 73505

United States, Oregon

Providence Portland Medical Center

Portland, Oregon, United States, 97213

United States, Rhode Island

Women and Infants Hospital

Providence, Rhode Island, United States, 02905

United States, South Dakota

Rapid City Regional Hospital

Rapid City, South Dakota, United States, 57701

United States, West Virginia

Edwards Comprehensive Cancer Center

Huntington, West Virginia, United States, 25701

United States, Wisconsin

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, United States, 54301

Sponsors and Collaborators

Academic and Community Cancer Research United

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Minetta C Liu; Academic and Community Cancer Research United

More Information

• Responsible Party: Academic and Community Cancer Research United
• ClinicalTrials.gov Identifier: NCT02037529
• Other Study ID Numbers: RU011201I; NCI-2016-02048 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); RU011201I ( Other Identifier: Academic and Community Cancer Research United ); P30CA015083 ( U.S. NIH Grant/Contract )
• First Posted: January 16, 2014
• Last Update Posted: May 26, 2022
• Last Verified: February 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Paclitaxel; Halichondrin B; Albumin-Bound Paclitaxel; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action